Home > Insider Trading > Filing (0001209191-21-023085)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1001233	Sangamo Therapeutics Inc	SGMO	Biological Products, (No Disgnostic Substances) (2836)	680359556

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1561733	Gary Loeb	C/O Sangamo Therapeutics, Inc. 7000 Marina Blvd Brisbane CA 94005	Evp, General Counsel & Sec.	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-03-23	11,981	$11.02	100,762	No	4	M	Direct
Common Stock	Disposition	2021-03-23	11,981	$13.10	88,781	No	4	S	Direct
Common Stock	Disposition	2021-03-23	5,000	$13.18	83,781	No	4	S	Direct
Common Stock	Disposition	2021-03-23	543	$13.17	83,238	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right-to-Buy)	Disposition	2021-03-23	11,981	$0.00	11,981	$11.02

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
238,019		2029-08-22	No	4	M	Direct

Footnotes

Includes 33,335 shares of common stock issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 25, 2020 that will vest in two remaining annual installments of 16,665 shares and 16,670 shares on February 25, 2022 and 2023 respectively, and 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third anniversary of the date of grant. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"), through such dates and subject to acceleration as defined in the 2018 EIP, as amended.
The option vested as to 1/4 of the total grant amount upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person, measured from the August 23, 2019 grant date, and the remainder vest and become exercisable in equal monthly installments for thirty-six months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date and subject to acceleration as provided in the 2018 EIP, as amended.